Smerud Medical Research Denmark   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Oslo Norway (1994)

Organization Overview

First Clinical Trial
2006
NCT00421746
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Smerud Medical Research Finland Ab/Oy | Smerud Medical Research Germany Ltd | Smerud Medical Research International AS | Smerud Medical Research International AS, Drammensveien 41, N-0271 Oslo, Norway

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Cystic Fibrosis (Phase 2)

Drug Overdose (Phase 1)

Eczema (Phase 4)

Fibrosis (Phase 2)

Heart Failure (Phase 2)

Hypertension (Phase 2)

Irritable Bowel Syndrome (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Phenylketonurias (Phase 4)

Prostatic Neoplasms (Phase 2)

Recurrence (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial APIs: 20